Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2004-04-1398PMID 15251980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

  2004cited by this paper
• Mutations

  2004cited by this paper
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

  2003cited by this paper
• Functional consequence of MDR1 expression on imatinib intracellular concentrations.

  2003cited by this paper
• RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

  2003cited by this paper
• Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

  2003cited by this paper
• Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.

  2003cited by this paper
• Variable expression of CYP and Pgp genes in the human small intestine

  2003cited by this paper
• Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

  2003cited by this paper
• Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

  2003cited by this paper
• Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.

  2002cited by this paper
• Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

  2002cited by this paper
• Imatinib. Novartis.

  2002cited by this paper
• Chronic myeloid leukemia: current treatment options.

  2001cited by this paper
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.

  2001cited by this paper
• STI571: a magic bullet?

  2001cited by this paper
• Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

  2001cited by this paper
• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  2001cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines

  1999cited by this paper
• Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin.

  1996cited by this paper

• rs2231142 (421 C>A, Q141K) Is More Functionally Influential than rs2231137 (34 G>A, V12M) on Anticancer Drug Resistance Mediated by the ABCG2 Haplotype In Vitro

  2025cites this paper
• Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs

  2025cites this paper
• The Role of the Bone Marrow Microenvironment in Leukemic Stem Cell Resistance: Pathways of Persistence and Selection.

  2025cites this paper
• Engineered Age‐Mimetic Breast Cancer Models Reveal Differential Drug Responses in Young and Aged Microenvironments

  2025cites this paper
• Tyrosine Kinase Inhibitors in Cancers: Treatment optimization - Part II.

  2024cites this paper
• Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs

  2024cites this paper
• Role of the RNA binding protein IGF2BP1 in cancer multidrug resistance.

  2024cites this paper
• Roles of the ABCG2 Transporter in Protoporphyrin IX Distribution and Toxicity

  2024cites this paper
• Engineered Age-Mimetic Breast Cancer Models Reveal Differential Drug Responses in Young and Aged Microenvironments

  2024cites this paper
• Successful Prediction of Fetal Exposure to Dual BCRP/P‐gp Drug Substrates Using the Efflux Ratio‐Relative Expression Factor Approach and PBPK M&S

  2023cites this paper
• Clinical outcomes of chemotherapy in cancer patients with different ethnicities

  2023cites this paper
• A Structure-Based View on ABC-Transporter Linked to Multidrug Resistance

  2023cites this paper
• Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia

  2023cites this paper
• Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy.

  2023cites this paper
• Cancer Stem Cells and Their Drug Resistance Mechanisms

  2023cites this paper
• Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis

  2023cites this paper
• Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment

  2022cites this paper
• Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

  2022cites this paper
• COVID-19 drugs: potential interaction with ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein

  2022cites this paper
• Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

  2022cites this paper
• Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models

  2022cites this paper
• Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model

  2022cites this paper
• A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo

  2021cites this paper
• The role of peptidases and their endogenous inhibitors in the regulation of NK cell cytotoxicity

  2021cites this paper
• ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans

  2021cites this paper
• The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment

  2021cites this paper
• Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study

  2021cites this paper
• Controversial link between proton pump inhibitors and anticancer agents: review of the literature

  2021cites this paper
• The Pharmacology of Xenobiotics after Intracerebro Spinal Fluid Administration: Implications for the Treatment of Brain Tumors

  2021cites this paper
• Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists

  2021cites this paper
• Recent progress on targeting leukemia stem cells.

  2021cites this paper
• ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates

  2021cites this paper
• Medically Important Alterations in Transport Function and Trafficking of ABCG2

  2021cites this paper
• Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells

  2020cites this paper
• Discovery of ABCG2/VEGFR2 Dual-Target Inhibitor With Anti-Drug Resistance Activity Based on the ATP Binding Site

  2020cites this paper
• The Role of JAK2 Gene in Imatinib-Resistant Chronic Myeloid Leukemia: A Review

  2020cites this paper
• Regulating Stem Cell-Related Genes Induces the Plastic Differentiation of Cancer Stem Cells to Treat Breast Cancer

  2020cites this paper
• ABCG2 transports anticancer drugs via a closed-to-open switch

  2020cites this paper
• Efflux transporters in cancer resistance: Molecular and functional characterization of breast cancer resistance protein

  2020cites this paper
• Structure-Activity Relationships of Efflux Transporter Inhibitors

  2019cites this paper
• Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia

  2019cites this paper
• Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives

  2019cites this paper
• Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

  2019cites this paper
• Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia

  2019cites this paper
• Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies

  2019cites this paper
• Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

  2019cites this paper
• A SYSTEMATIC REVIEW ON SELF-MICRO EMULSIFYING DRUG DELIVERY SYSTEMS: A POTENTIAL STRATEGY FOR DRUGS WITH POOR ORAL BIOAVAILABILITY

  2019cites this paper
• SNAIL- and SLUG-induced side population phenotype of HCT116 human colorectal cancer cells and its regulation by BET inhibitors.

  2019cites this paper
• : Chronic Myeloid Leukemia : Stem Cell Niche and Response to Pharmacologic Treatment

  2018cites this paper
• Elucidating the role of TGFβ signalling in drug resistant Hh driven cancers

  2018cites this paper
• Enantioselective Drug Recognition by Drug Transporters

  2018cites this paper
• Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function, drug penetration, and antibody shuttling properties

  2018cites this paper
• Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines

  2018cites this paper
• Pluripotent Stem Cell Platforms for Drug Discovery.

  2018influential citation
• Overview of Transporters in Pharmacokinetics and Drug Discovery

  2018cites this paper
• Interindividual Regulation of the Breast Cancer Resistance Protein/ABCG2 Transporter in Term Human Placentas

  2018cites this paper
• Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.

  2018cites this paper
• Lipid regulation of placental mycotoxin transport

  2018cites this paper
• Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines

  2018cites this paper
• Metabolic Reprogramming During Multidrug Resistance in Leukemias

  2018cites this paper
• Small‐molecule inhibitors of multidrug resistance‐associated protein 1 and related processes: A historic approach and recent advances

  2018cites this paper
• Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.

  2017cites this paper
• Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

  2017cites this paper
• The Xenobiotic-Metabolising System in Human Immune Cells

  2017cites this paper
• 2 From where do Cancer-Initiating Cells Originate ?

  2017cites this paper
• Monitoring plasma imatinib level to improve results of therapy of chronic myeloid leukosis

  2017cites this paper
• Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia

  2017cites this paper
• Molecular Bases of Chemoresistance in Cholangiocarcinoma.

  2017cites this paper
• Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia‐inducible factors HIF1α and HIF2α

  2017cites this paper
• Reducing Interstitial Fluid Pressure and Inhibiting Pulmonary Metastasis of Breast Cancer by Gelatin Modified Cationic Lipid Nanoparticles.

  2017cites this paper
• In vitro evaluation of the efficacy of selected medicinal plant extracts against multidrug resistant cancer cells

  2017cites this paper
• Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT 3-Dependent NF-κB and HSP 27 / p 38 / AKT Pathways and by Inhibiting ABCB 1 Jonathan

  2017cites this paper
• Prédiction in silico de l'absorption intestinale et de la pénétration cérébrale des pesticides chez l'homme

  2017cites this paper
• Metabolism of KO143, an ABCG2 inhibitor.

  2017cites this paper
• Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels.

  2017cites this paper
• Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.

  2017cites this paper
• ABCB1 genetic variants in leukemias: current insights into treatment outcomes

  2017cites this paper
• Dynamics of Expression of Drug Transporters: Methods for Appraisal.

  2016cites this paper
• Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors

  2016cites this paper
• The Effect of Human Pluripotent Stem Cell Platforms on Preclinical Drug Development

  2016cites this paper
• Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.

  2016cites this paper
• Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

  2016cites this paper
• [Role of breast cancer resistance protein in drug disposition].

  2016cites this paper
• Effect of Disease Pathologies on Transporter Expression and Function

  2016cites this paper
• Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes

  2016cites this paper
• Roles of ATP binding cassette transporters in drug sensitivity and physiology of Plasmodium parasites

  2016cites this paper
• Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.

  2016cites this paper
• The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview

  2016cites this paper
• Biomarkers for Determining the Prognosis of CML

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors

  2016cites this paper
• ABCG 2 C 421 A Polymorphism and Imatinib Response in Chronic Myeloid Leukemia : A Systematic Review and Meta-Analysis

  2016cites this paper
• Drug–drug interactions with imatinib

  2016cites this paper
• Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.

  2016cites this paper
• Microsoft Word-79110970-file00

  2015cites this paper
• Lysosomal Sequestration Determines Intracellular Imatinib Levels

  2015cites this paper
• Regulation of lysophosphatidate-induced mechanisms of chemo-resistance

  2015cites this paper
• Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.

  2015cites this paper
• The Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors

  2015cites this paper